ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024
Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping to estimate health state utility: a systematic review of development and limitations.Health and quality of life outcomes · 2025Pooled it
- A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Quality-Adjusted Life Expectancy and Cost-Effectiveness Thresholds in Three High-Income Regions in Asia.Applied health economics and health policy · 2026Article
- A comparative study of EQ-5D-5L and SF-6D scales based on patients receiving oral anticoagulant therapy.Health and quality of life outcomes · 2026Article
- Article
- Assessment of health-related quality of life of patients with gout and hyperuricemia in the Tianjin area according to the SF-6Dv2 scale.Frontiers in public health · 2026Article
- Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among patients with diabetes in China.Health and quality of life outcomes · 2025Article
- Evaluation of measurement properties of the Health Assessment Questionnaire-Disability Index (HAQ-DI) among gout patients in China.Health and quality of life outcomes · 2025Article
- Validation and comparison of EQ-5D-5L and SF-6Dv1 in myopic patients requiring corneal refractive surgery in China.Health and quality of life outcomes · 2025Article
- Health-related quality of life of patients with multiple sclerosis in China: a national online survey.Health and quality of life outcomes · 2025Article
- Mapping the ADDQoL to the EQ-5D-5L and SF-6Dv2 among Chinese patients with type 2 diabetes mellitus.Health and quality of life outcomes · 2025Article
- Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China.Frontiers in oncology · 2025Article
- The generic version of China Health Related Outcomes Measures (CHROME-G): psychometric testing and comparative performance with the EQ-5D-5L and SF-6Dv2 among the Chinese general population.BMC public health · 2024Article
- Evaluation of measurement properties of the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument among Chinese overweight and obese populations.Health and quality of life outcomes · 2024Article
- Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Health-related quality of life assessed by EQ-5D-5L and its determinants among Chinese adults.Frontiers in public health · 2024Article
- Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China.Health and quality of life outcomes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesTo explore the comparative performance and develop the mapping algorithms between EQ-5D-5L and SF-6Dv2 in China.
methodsRespondents recruited from the Chinese general population completed both EQ-5D-5L and SF-6Dv2 during face-to-face interviews. Ceiling/floor effects were reported. Discriminative validity in self-reported chronic conditions was investigated using the effect sizes (ES). Test-retest reliability was evaluated using intra-class correlation coefficient (ICC) and Bland-Altman plots in a subsample. Correlation and absolute agreements between the two measures were estimated with Spearman's rank correlation coefficient and ICC, respectively. Ordinary least squares (OLS), generalized linear model, Tobit model, and robust MM-estimator were explored to estimate mapping equations between EQ-5D-5L and SF-6Dv2.
results3320 respondents (50.3% males; age 18-90 years) were recruited. 51.1% and 12.2% of respondents reported no problems on all EQ-5D-5L and SF-6Dv2 dimensions, respectively. The mean EQ-5D-5L utility was higher than SF-6Dv2 (0.947 vs. 0.827, p < 0.001). Utilities were significantly different across all chronic conditions groups for both measures. The mean absolute difference of utilities between the two tests for EQ-5D-5L was smaller (0.033 vs. 0.043) than SF-6Dv2, with a slightly higher ICC (0.859 vs. 0.827). Fair agreement (ICC = 0.582) was observed in the utilities between the two measures. Mapping algorithms generated by the OLS models performed the best according to the goodness-of-fit indicators.
conclusionsBoth measures showed comparable discriminative validity. Systematic differences in utilities were found, and on average, the EQ-5D-5L generates higher values than the SF-6Dv2. Mapping algorithms between the EQ-5D-5L and SF-6Dv2 are reported to enable transformations between these two measures in China.
Indexed as
Identifiers
36709458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.